[31]Although cancer may escape from immune-mediated detection via the PD-1/ PD-L2 axis under PD-L1 inhibitor treatment, it also implies that PD-L1 inhibitor may have weaker autoimmunity, thus resulting in less immune-mediated cardiotoxicity. The gene discussed is PDCD1LG2; the disease is cancer.